Cogent Biosciences, Inc. Announces Pricing of Public Offering, Generating Approximately $150 Million for Precision Therapies Development

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 12,500,000 shares of its common stock, offered at a public offering price of $12.00 per share.